Business

Pharming Group to participate in Oppenheimer Movers in Rare Disease Summit

Leiden, the Netherlands, December 8, 2025: Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) today announced its participation in the Oppenheimer Movers in Rare Disease Summit on December 11, 2025 in New York City. This invitation-only event brings together innovative companies and investors focused on rare diseases. Anurag Relan, M.D., Chief Medical Officer of Pharming, will participate in a fireside chat focused on the hereditary angioedema (HAE) market at 1:50 pm ET /

Pharming Group NvDecember 8, 20251
Pharming Group to participate in Oppenheimer Movers in Rare Disease Summit

About this update from Pharming Group Nv

Leiden, the  Netherlands, December 8, 2025: Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) today announced its participation in the Oppenheimer Movers in Rare Disease Summit on December 11, 2025 in New York City. This invitation-only event brings together innovative companies and investors focused on rare diseases. Anurag Relan, M.D., Chief Medical Officer of Pharming, will participate in a fireside chat focused on the hereditary angioedema (HAE) market at 1:50 pm ET / 19:50 CET. To schedule a one-on-one meeting with Pharming’s management team, please contact Investor Relations at [email protected] or your Oppenheimer representative. About Pharming Group N.V. Pharming Group N.V. (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) is a global biopharmaceutical company dedicated to transforming the lives of patients with rare, debilitating, and life-threatening diseases. We are developing and commercializing a portfolio of innovative medicines, including small molecules and biologics. Pharming is headquartered in Leiden, the Netherlands, with a significant proportion of its employees based in the U.S. For more information, visit www.pharming.com and find us on LinkedIn . For further public information, contact: Investor Relations Michael Levitan, VP Investor Relations & Corporate Communications T: +1 (908) 705 1696 E: [email protected] Media Relations Global: Saskia Mehring, Corporate Communications Manager T: +31 6 28 32 60 41 E: [email protected] U.S.: Ethan Metelenis (Precision AQ on behalf of Pharming) T: +1 (917) 882-9038 Netherlands: Leon Melens (LifeSpring Life Sciences Communication on behalf of Pharming) T: +31 6 53 81 64 27 Attachment

View stock analysis, news, and events for Pharming Group Nv

Euronext AmsterdamPharming Group N.V.Investor RelationsLeiden, the NetherlandsPHAROppenheimer MoversRare DiseaseChief Medical OfficerAnurag Relan

More from Pharming Group Nv

All Pharming Group Nv news →